{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T12:14:36Z","timestamp":1767183276401,"version":"3.37.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-022-04239-1","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T10:03:34Z","timestamp":1670580214000},"page":"2033-2041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6935-3873","authenticated-orcid":false,"given":"Michael","family":"Baboudjian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00eblle","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Gauth\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Beauval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Barret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Brureau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00eblle","family":"Fiard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Ruffion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00eble","family":"Renard-Penna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Prostate Cancer Committee of the French Association of Urology","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"1","key":"4239_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8\u201310","journal-title":"J Clin Oncol"},{"key":"4239_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3389\/fonc.2012.00215","volume":"2","author":"KA Ahmed","year":"2013","unstructured":"Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR (2013) Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 2:215","journal-title":"Front Oncol"},{"issue":"12","key":"4239_CR3","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.2967\/jnumed.115.162610","volume":"56","author":"R Minamimoto","year":"2015","unstructured":"Minamimoto R, Loening A, Jamali M et al (2015) Prospective comparison of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG PET\/CT, and whole-body MRI in patients with breast and prostate cancer. J Nucl Med 56(12):1862\u20131868","journal-title":"J Nucl Med"},{"issue":"4","key":"4239_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","volume":"63","author":"AM H\u00f6vels","year":"2008","unstructured":"H\u00f6vels AM, Heesakkers RA, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63(4):387\u2013395","journal-title":"Clin Radiol"},{"issue":"25","key":"4239_CR5","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1056\/NEJMoa022749","volume":"348","author":"MG Harisinghani","year":"2003","unstructured":"Harisinghani MG, Barentsz J, Hahn PF et al (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348(25):2491\u20132499","journal-title":"N Engl J Med"},{"issue":"8","key":"4239_CR6","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","volume":"26","author":"S Gillessen","year":"2015","unstructured":"Gillessen S, Omlin A, Attard G et al (2015) Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26(8):1589\u20131604","journal-title":"Ann Oncol"},{"issue":"1","key":"4239_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2013.04.019","volume":"64","author":"MH Umbehr","year":"2013","unstructured":"Umbehr MH, M\u00fcntener M, Hany T, Sulser T, Bachmann LM (2013) The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET\/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 64(1):106\u2013117","journal-title":"Eur Urol"},{"issue":"10231","key":"4239_CR8","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395(10231):1208\u20131216","journal-title":"Lancet"},{"key":"4239_CR9","first-page":"342","volume":"59","author":"JR Garcia","year":"2015","unstructured":"Garcia JR, Jorcano S, Soler M et al (2015) 11C-Choline PET\/CT in the primary diagnosis of prostate cancer: impact on treatment planning. Q J Nucl Med Mol Imaging 59:342\u2013350","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"4239_CR10","first-page":"72","volume":"40","author":"JR Garcia","year":"2021","unstructured":"Garcia JR, Compte A, Galan C et al (2021) 18F-choline PET\/MRI on initial staging of prostate cancer. Impact on therapy approach. Rev Esp Med Nucl Imagen Mol (Engl Ed) 40:72\u201381","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"4239_CR11","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00259-021-05655-y","volume":"49","author":"M Kesler","year":"2022","unstructured":"Kesler M, Kerzhner K, Druckmann I et al (2022) Staging 68 Ga-PSMA PET\/CT in 963 consecutive patients with newly diagnosed prostate cancer: incidence and characterization of skeletal involvement. Eur J Nucl Med Mol Imaging 49:2077\u20132085","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4239_CR12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ijrobp.2017.06.2448","volume":"99","author":"SK Gupta","year":"2017","unstructured":"Gupta SK, Watson T, Denham J et al (2017) Prostate-specific membrane antigen positron emission tomography-computed tomography for prostate cancer: distribution of disease and implications for radiation therapy planning. Int J Radiat Oncol Biol Phys 99:701\u2013709","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4239_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4274\/mirt.galenos.2020.89421","volume":"29","author":"M Erdo\u011fan","year":"2020","unstructured":"Erdo\u011fan M, \u00d6zkan EE, \u00d6zt\u00fcrk SA, Y\u0131ld\u0131z M, \u015eeng\u00fcl SS (2020) The role of Ga-68 PSMA PET\/CT scan on differentiating of oligometastatic and high risk prostate cancer. Mol Imaging Radionucl Ther 29:98\u2013104","journal-title":"Mol Imaging Radionucl Ther"},{"key":"4239_CR14","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. The Lancet 395:1208\u20131216","journal-title":"The Lancet"},{"issue":"3","key":"4239_CR15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boev\u00e9","year":"2019","unstructured":"Boev\u00e9 LMS, Hulshof MCCM, Vis AN et al (2019) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol 75(3):410\u2013418","journal-title":"Eur Urol"},{"issue":"10162","key":"4239_CR16","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353\u20132366","journal-title":"Lancet"},{"issue":"6","key":"4239_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003998","volume":"19","author":"CC Parker","year":"2022","unstructured":"Parker CC, James ND, Brawley CD et al (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial. PLoS Med 19(6):e1003998","journal-title":"PLoS Med"},{"issue":"1","key":"4239_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","volume":"76","author":"S Burdett","year":"2019","unstructured":"Burdett S, Boev\u00e9 LM, Ingleby FC et al (2019) Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur Urol 76(1):115\u2013124","journal-title":"Eur Urol"},{"issue":"6","key":"4239_CR19","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","volume":"65","author":"SH Culp","year":"2014","unstructured":"Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 65(6):1058\u20131066","journal-title":"Eur Urol"},{"issue":"5","key":"4239_CR20","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.eururo.2015.05.023","volume":"69","author":"P Sooriakumaran","year":"2016","unstructured":"Sooriakumaran P, Karnes J, Stief C et al (2016) A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 69(5):788\u2013794","journal-title":"Eur Urol"},{"key":"4239_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.euros.2021.05.006","volume":"29","author":"N Lumen","year":"2021","unstructured":"Lumen N, De Bleser E, Buelens S et al (2021) The role of cytoreductive radical prostatectomy in the treatment of newly diagnosed low-volume metastatic prostate cancer. Results from the local treatment of metastatic prostate cancer (LoMP) registry. Eur Urol Open Sci 29:68\u201376","journal-title":"Eur Urol Open Sci"},{"issue":"5","key":"4239_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.euo.2022.06.001","volume":"5","author":"B Dai","year":"2022","unstructured":"Dai B, Zhang S, Wan FN et al (2022) Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial. Eur Urol Oncol 5(5):519\u2013525","journal-title":"Eur Urol Oncol"},{"issue":"12","key":"4239_CR23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/pros.23645","volume":"78","author":"E Francini","year":"2018","unstructured":"Francini E, Gray KP, Xie W et al (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78(12):889\u2013895","journal-title":"Prostate"},{"issue":"9","key":"4239_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41571-022-00655-9","volume":"19","author":"RR Katipally","year":"2022","unstructured":"Katipally RR, Pitroda SP, Juloori A, Chmura SJ, Weichselbaum RR (2022) The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol 19(9):585\u2013599","journal-title":"Nat Rev Clin Oncol"},{"issue":"25","key":"4239_CR25","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38(25):2830\u20132838","journal-title":"J Clin Oncol"},{"issue":"5","key":"4239_CR26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446\u2013453","journal-title":"J Clin Oncol"},{"issue":"5","key":"4239_CR27","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6(5):650\u2013659","journal-title":"JAMA Oncol"},{"issue":"1","key":"4239_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/ijc.32509","volume":"146","author":"P Bowden","year":"2020","unstructured":"Bowden P, See AW, Frydenberg M et al (2020) Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: interim outcomes of a prospective clinical trial. Int J Cancer 146(1):161\u2013168","journal-title":"Int J Cancer"},{"issue":"1","key":"4239_CR29","doi-asserted-by":"publisher","first-page":"17471","DOI":"10.1038\/s41598-020-74562-3","volume":"10","author":"C Reverberi","year":"2020","unstructured":"Reverberi C, Massaro M, Osti MF et al (2020) Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer. Sci Rep 10(1):17471","journal-title":"Sci Rep"},{"issue":"1108","key":"4239_CR30","doi-asserted-by":"publisher","first-page":"20190353","DOI":"10.1259\/bjr.20190353","volume":"93","author":"CL Deantoni","year":"2020","unstructured":"Deantoni CL, Fodor A, Cozzarini C et al (2020) Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases. Br J Radiol 93(1108):20190353","journal-title":"Br J Radiol"},{"issue":"7","key":"4239_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s12032-020-01385-7","volume":"37","author":"DK Reyes","year":"2020","unstructured":"Reyes DK, Rowe SP, Schaeffer EM et al (2020) Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer. Med Oncol 37(7):60","journal-title":"Med Oncol"},{"issue":"11","key":"4239_CR32","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 36(11):1080\u20131087","journal-title":"J Clin Oncol"},{"issue":"2","key":"4239_CR33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis G, Boher JM, Joly F et al (2016) Androgen Deprivation Therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 70(2):256\u2013262","journal-title":"Eur Urol"},{"issue":"12","key":"4239_CR34","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","volume":"30","author":"NW Clarke","year":"2019","unstructured":"Clarke NW, Ali A, Ingleby FC et al (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 30(12):1992\u20132003","journal-title":"Ann Oncol"},{"issue":"5","key":"4239_CR35","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20(5):686\u2013700","journal-title":"Lancet Oncol"},{"issue":"3","key":"4239_CR36","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ijc.34018","volume":"151","author":"ND James","year":"2022","unstructured":"James ND, Clarke NW, Cook A et al (2022) Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer 151(3):422\u2013434","journal-title":"Int J Cancer"},{"issue":"15","key":"4239_CR37","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T et al (2022) Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 40(15):1616\u20131622","journal-title":"J Clin Oncol"},{"issue":"20","key":"4239_CR38","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39(20):2294\u20132303","journal-title":"J Clin Oncol"},{"issue":"17_suppl","key":"4239_CR39","doi-asserted-by":"publisher","first-page":"LBA5004","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA5004","volume":"40","author":"ID Davis","year":"2022","unstructured":"Davis ID, Martin AJ, Zielinski RR et al (2022) Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol 40(17_suppl):LBA5004","journal-title":"J Clin Oncol"},{"issue":"10336","key":"4239_CR40","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J et al (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet 399(10336):1695\u20131707","journal-title":"Lancet"},{"issue":"12","key":"4239_CR41","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386(12):1132\u20131142","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"4239_CR42","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1200\/JCO.2022.40.16_suppl.5070","volume":"40","author":"CL Vale","year":"2022","unstructured":"Vale CL, Fisher D, Godolphin P et al (2022) Defining more precisely the effects of docetaxel plus ADT for men with mHSPC: meta-analysis of individual participant data from randomized trials. J Clin Oncol 40(16_suppl):5070","journal-title":"J Clin Oncol"},{"issue":"22","key":"4239_CR43","doi-asserted-by":"publisher","first-page":"S2588","DOI":"10.1016\/j.euo.2022.04.007","volume":"11","author":"D Menges","year":"2022","unstructured":"Menges D, Yebyo HG, Sivec-Muniz S (2022) Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment. Eur Urol Oncol 11(22):S2588\u201393. https:\/\/doi.org\/10.1016\/j.euo.2022.04.007","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"4239_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2022.04.002","volume":"82","author":"S Gillessen","year":"2022","unstructured":"Gillessen S, Armstrong A, Attard G et al (2022) Management of patients with advanced prostate cancer: report from the advanced prostate cancer consensus conference 2021. Eur Urol 82(1):115\u2013141","journal-title":"Eur Urol"},{"issue":"26","key":"4239_CR45","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1200\/JCO.22.00208","volume":"140","author":"M Hussain","year":"2022","unstructured":"Hussain M, Carducci MA, Clarke N (2022) Evolving role of prostate-specific membrane antigen-positron emission tomography in metastatic hormone-sensitive prostate cancer: more questions than answers? J Clin Onco l40(26):3011\u20133014. https:\/\/doi.org\/10.1200\/JCO.22.00208","journal-title":"J Clin Onco"},{"key":"4239_CR46","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2021.11.026","volume":"162","author":"G Baciarello","year":"2022","unstructured":"Baciarello G, \u00d6zg\u00fcro\u011flu M, Mundle S et al (2022) Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: a post-hoc exploratory analysis of the LATITUDE study. Eur J Cancer 162:56\u201364","journal-title":"Eur J Cancer"},{"issue":"4","key":"4239_CR47","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","volume":"36","author":"LC Harshman","year":"2018","unstructured":"Harshman LC, Chen YH, Liu G et al (2018) Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel. J Clin Oncol 36(4):376\u2013382","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"4239_CR48","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1200\/JCO.2022.40.16_suppl.5078","volume":"40","author":"F Saad","year":"2022","unstructured":"Saad F, Hussain MHA, Tombal BF et al (2022) Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial. J Clin Oncol 40(16_suppl):5078","journal-title":"J Clin Oncol"},{"issue":"18","key":"4239_CR49","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.3390\/cancers13184522","volume":"13","author":"C Cattrini","year":"2021","unstructured":"Cattrini C, Espa\u00f1a R, Mennitto A et al (2021) Optimal sequencing and predictive biomarkers in patients with advanced prostate cancer. Cancers (Basel) 13(18):4522","journal-title":"Cancers (Basel)"},{"issue":"9","key":"4239_CR50","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.annonc.2021.06.003","volume":"32","author":"AA Hamid","year":"2021","unstructured":"Hamid AA, Huang HC, Wang V et al (2021) Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Ann Oncol 32(9):1157\u20131166","journal-title":"Ann Oncol"},{"issue":"6","key":"4239_CR51","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro E, Romero-Laorden N, Del Pozo A et al (2019) PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol 37(6):490\u2013503","journal-title":"J Clin Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04239-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-022-04239-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04239-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T12:15:16Z","timestamp":1691669716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-022-04239-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["4239"],"URL":"https:\/\/doi.org\/10.1007\/s00345-022-04239-1","relation":{},"ISSN":["1433-8726"],"issn-type":[{"type":"electronic","value":"1433-8726"}],"subject":[],"published":{"date-parts":[[2022,12,9]]},"assertion":[{"value":"14 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this study design (i.e., review), ethical approval is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this study design (i.e., review), informed consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors approve the submission.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}